A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP
Purpose. Docetaxel/5-FU/CDDP (DFP) therapy is a useful treatment for advanced esophageal cancer. However, adverse reactions such as chemotherapy-induced nausea and vomiting (CINV) interfere often with continuation of the chemotherapy. We investigated the efficacy of rikkunshito (TJ-43) on CINV. Meth...
Main Authors: | Junichi Seike, Toru Sawada, Naoya Kawakita, Yota Yamamoto, Yasuhiro Yuasa, Hiromichi Yamai, Hirokazu Takachi, Takahiro Yoshida, Akira Tangoku |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | International Journal of Surgical Oncology |
Online Access: | http://dx.doi.org/10.1155/2011/715623 |
Similar Items
-
Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line
by: Si Ming Xie, et al.
Published: (2010-01-01) -
Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome
by: Naoki eFujitsuka, et al.
Published: (2014-12-01) -
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use
by: Neng-Sheng Chu, et al.
Published: (2018-03-01) -
Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice
by: Hiromichi Wakui, et al.
Published: (2020-02-01) -
Rikkunshito Ameliorates Cancer Cachexia Partly through Elevation of Glucarate in Plasma
by: Katsuya Ohbuchi, et al.
Published: (2015-01-01)